Cabaletta Bio Q3 2026 net loss widens to $53.1M
Cabaletta expects its cash position to fund operations into the first quarter of 2028 as registrational myositis results are expected in the second half of 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cabaletta Bio, Inc. reported third-quarter 2026 financial results and clinical-program updates. Research and development expense was $47.144 million, compared with $39.824 million in the same period of 2025; general and administrative expense was $7.563 million, compared with $6.764 million. Net loss was $53.053 million, versus $44.866 million, and basic and diluted net loss per share was $0.28, versus $0.44.
Cash and cash equivalents were approximately $299.4 million as of September 30, 2026, including approximately $115.0 million from common-stock warrant exercises between July 1, 2026 and the warrants’ expiration on September 12, 2026. Cabaletta expects this cash position to fund its operating plan into the first quarter of 2028. The 17-patient registrational myositis cohort is expected to report topline results in the second half of 2027 to support a planned BLA submission in the first quarter of 2028; the company plans to include juvenile dermatomyositis data for a potential pediatric indication and potential Priority Review Voucher eligibility. Cabaletta initiated an approximately 25-patient registrational systemic-sclerosis cohort focused on interstitial lung disease and plans to announce PC-free program development plans in the first half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Cash and cash equivalents of approximately $299.4 million are expected to fund operations into 1Q28.
- Moderate pointPer-share loss narrowed to $0.28 from $0.44 in 3Q25.
Negative
- Moderate pointNet loss increased to $53.053 million from $44.866 million in 3Q25.
Filing Explained
For systemic sclerosis, five patients with interstitial lung disease had an average predicted-FVC improvement of about
8-K Event Classification
Key Figures
Key Terms
resecabtagene autoleucel medical
chimeric antigen receptor (CAR) T cell therapy medical
preconditioning-free (PC-free) medical
Biologics License Application (BLA) regulatory
Priority Review Voucher (PRV) regulatory
Earnings Snapshot
Cabaletta expects its cash position as of September 30, 2026 to fund its operating plan into the first quarter of 2028.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash does CABA have, and how long is it expected to last?
When does CABA expect myositis results and a BLA submission?
What is CABA's RESET-SSc primary endpoint?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
99.1 |
|
Press Release issued by the registrant on November 5, 2026, furnished herewith. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
CABALETTA BIO, INC. |
|
|
|
|
|
Date: November 5, 2026 |
|
By: |
/s/ Steven Nichtberger |
|
|
|
Steven Nichtberger |
|
|
|
Chief Executive Officer and President (Principal Executive Officer) |
Exhibit 99.1
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data
Immunomodulator-free durability data from the complete Phase 1/2 dermatomyositis cohort at one year and from the complete Phase 1/2 lupus nephritis cohort with follow-up as long as two years as well as updated safety data from the RESET™ program with preconditioning to be presented during ACR Convergence 2026
RESET-SSc® registrational cohort initiated in systemic sclerosis patients with interstitial lung disease including endpoints evaluating improvement of lung function and overall disease
PC-free program advancing with maturing data expected to inform 1H27 go-forward clinical development plans
Operational runway extended into 1Q28 with $299.4 million cash position as of September 30, 2026
PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety,” said Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta. “We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field. Additionally, we are excited by progress in our juvenile dermatomyositis program and expect to have a robust dataset from these patients to include with our planned BLA submission in myositis in the first quarter of 2028, potentially enabling our eligibility for a Priority Review Voucher. We also initiated our second registrational study to evaluate the ability of rese-cel to improve lung function and overall disease in systemic sclerosis, a patient population with one of the highest mortality rates among rheumatological conditions. In parallel, our PC-free program continues to build toward a dataset that will guide our path forward on the optimal dose and development strategy, which we plan to announce in the first half of 2027.”
Recent Operational Highlights and Anticipated Upcoming Milestones
Resecabtagene autoleucel (rese-cel) for autoimmune diseases
Rese-cel is an investigational chimeric antigen receptor (CAR) T cell therapy designed to achieve a potential immune reset in patients living with autoimmune diseases. Following a single, weight-based intravenous infusion after discontinuation of immunomodulators, rese-cel has shown the ability to deliver an immune reset, leading to clinical responses that have sustained over time. Cabaletta is evaluating rese-cel across the REstoring SElf-Tolerance (RESET™) clinical development program, which includes multiple single-arm, company-sponsored trials in rheumatology, neurology, and dermatology with disease-specific cohorts designed to evolve directly into registrational studies. Cabaletta is also advancing a program of innovations to broaden and deepen the treatment potential of rese-cel across autoimmune diseases.
RESET-Myositis registrational topline results expected 2H27 to support planned BLA submission in 1Q28
RESET-SSc registrational cohort initiated and open for patient enrollment
Prioritized PC-free trials generating dose optimization insights for 1H27 go-forward clinical development plans
Recent external scientific presentations
Upcoming presentations and Innovation Theater at ACR Convergence 2026
Third Quarter 2026 Financial Results
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, resecabtagene autoleucel (rese-cel), is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the REstoring SElf-Tolerance (RESET™) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta’s business plans and objectives as a whole; Cabaletta’s ability to realize its vision of launching curative targeted cell therapies designed specifically for patients with autoimmune diseases; Cabaletta’s ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta’s clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support rese-cel’s safety and activity profile; statements regarding the timing of interactions with the FDA, including review of safety information from Cabaletta’s ongoing clinical trials and discussions with the FDA on potential registrational pathways for rese-cel, including the timing and acceptance of registrational designs related thereto; Cabaletta's expectations regarding the timing of topline results from the registrational DM/ASyS cohort in the second half of 2027 and its plans to submit a BLA for rese-cel in myositis, inclusive of adult and juvenile DM data, in 1Q28; Cabaletta's expectations regarding the inclusion of multi-year Phase 1/2 myositis durability data in its planned BLA submission based on its recent Type B regulatory interaction with the FDA; Cabaletta's expectations regarding the potential eligibility for a Priority Review Voucher based on a potential pediatric indication for juvenile DM; Cabaletta's plans and expectations regarding the registrational RESET-SSc cohort in systemic sclerosis-associated interstitial lung disease, including enrollment, trial design, and timing of data read-outs; significance of the clinical data read-out at upcoming scientific meetings and timing thereof; Cabaletta’s expectations around the potential success and therapeutic benefits of rese-cel; the advancement of clinical trials of rese-cel in patients with SLE, myositis, SSc, gMG and PV, including updates related to status, enrollment, safety data, trial design and timing of data read-outs or otherwise; Cabaletta’s plans and expectations regarding the timing and results of clinical data from patients treated with rese-cel without preconditioning; Cabaletta’s plans to generate dose optimization insights from its PC-free trials across multiple autoimmune indications and to announce go-forward clinical development plans in the first half of 2027; Cabaletta's expectations regarding the safety profile of rese-cel and its belief that such profile supports outpatient administration and Cabaletta's plans to expand the outpatient dosing option across the RESET clinical development program; and Cabaletta’s use of capital, expense and other financial results in the future and its ability to fund its operating plan into the first quarter of 2028.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to regulatory filings and potential clearance; the risk that preclinical or clinical data, including signs of biologic activity or clinical response, may not be predictive of
long-term results or translate across programs; Cabaletta’s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of rese-cel; the risk that the results observed with the similarly-designed construct employed in academic publications, including due to the dosing regimen, are not indicative of the results Cabaletta seeks to achieve with rese-cel; risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabaletta’s ability to retain and recognize the intended incentives conferred by Orphan Drug Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or other designations for its product candidates, as applicable; risks related to Cabaletta’s ability to protect and maintain its intellectual property position; risks related to fostering and maintaining successful relationships with Cabaletta’s collaboration and manufacturing partners; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Cabaletta’s product candidates will not be successfully developed and/or commercialized; and the risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Cabaletta’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta’s other subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.
CABALETTA BIO, INC.
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
Statements of Operations
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
Unaudited |
|
|
Unaudited |
|
||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
47,144 |
|
|
$ |
39,824 |
|
|
$ |
128,927 |
|
|
$ |
106,480 |
|
General and administrative |
|
|
7,563 |
|
|
|
6,764 |
|
|
|
22,097 |
|
|
|
23,150 |
|
Total operating expenses |
|
|
54,707 |
|
|
|
46,588 |
|
|
|
151,024 |
|
|
|
129,630 |
|
Loss from operations |
|
|
(54,707 |
) |
|
|
(46,588 |
) |
|
|
(151,024 |
) |
|
|
(129,630 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
2,144 |
|
|
|
1,808 |
|
|
|
4,824 |
|
|
|
4,705 |
|
Interest expense |
|
|
(511 |
) |
|
|
(584 |
) |
|
|
(1,664 |
) |
|
|
(1,449 |
) |
Other income, net |
|
|
21 |
|
|
|
498 |
|
|
|
278 |
|
|
|
437 |
|
Net loss |
|
$ |
(53,053 |
) |
|
$ |
(44,866 |
) |
|
$ |
(147,586 |
) |
|
$ |
(125,937 |
) |
Net loss per common stock share, basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(0.44 |
) |
|
$ |
(0.98 |
) |
|
$ |
(1.75 |
) |
Selected Balance Sheet Data
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
Unaudited |
|
|||||
Cash, cash equivalents and short-term investments |
|
$ |
299,383 |
|
|
$ |
133,599 |
|
Total assets |
|
|
336,491 |
|
|
|
165,083 |
|
Total liabilities |
|
|
52,572 |
|
|
|
53,032 |
|
Total stockholders’ equity |
|
|
283,919 |
|
|
|
112,051 |
|
Contacts
Investors: investors@cabalettabio.com
Media: media@cabalettabio.com